Johnson & Johnson at Guggenheim Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Vamil Divan - Guggenheim Partners, LLC - Analyst : So I think three main areas I want to sort of touch on, and I think there's obviously more we could go into. One is your work in lung cancer; second would be the progress you're making in the bladder cancer side; and then third, your sort of dominant position in myeloma and the steps you're taking there. So let's start with lung cancer first. I think that's the one of the three where I feel like there might be -- bladder, we could argue too. But I think lung where I think you guys have some interesting data, but I think definitely a disconnect between how Johnson & Johnson is seeing the opportunity and where the Street is seeing things right now. So maybe just the progress you've made with RYBREVANT so far, any updates on the sub-Q and the sort of the tolerability, patient experience side of things. And then we have a couple of detailed questions after that, but I'll let you kick it off.

Question: Vamil Divan - Guggenheim Partners, LLC - Analyst : So maybe one quick follow up on some of the comments. So the uptake you're seeing so far, can you describe it in any way? What patients or what -- it sounds like it's a pretty broad community and academic center. So who's making the decision to use this over the other options that are available?

Question: Vamil Divan - Guggenheim Partners, LLC - Analyst : Okay. Let me turn to Edouard to kind of dive into the bladder cancer side.

Question: Vamil Divan - Guggenheim Partners, LLC - Analyst : Let me see if there's any questions in the audience. Otherwise, we'll shift gears over to the myeloma side. Obviously, tremendous success that Johnson & Johnson's had there. I'll stick to a few of the key questions we've been getting from investors, one around CARVYKTI. Nice sequential growth we're finally seeing here, with the manufacturing capacity picking up here. I think a little bit of questions on the sort of competitive side of things, especially with ASH coming up. So just if you can talk about, obviously, the profile you've built up for your products so far to date, but also I think questions around the safety and kind of how that might hold up relative to competition. Just your perspective as we head into ASH in a few weeks.

Question: Vamil Divan - Guggenheim Partners, LLC - Analyst : So then, kind of talking broader portfolio here. You obviously have the bispecifics now on the market as well. Another common question we get is how does this all sort of fit in together? How do you sort of personalize there? How are you sort of thinking about which patients might be best to get the bispecifics versus -- than CARVYKTI? How does TECVAYLI and TALVEY sort of fit together? So maybe we can just talk about the bispecifics, their uptake so far, which patients tend to be maybe preferring that approach over the cell therapy approaches, and how do you see that as they're evolving going forward.

Question: Vamil Divan - Guggenheim Partners, LLC - Analyst : Okay. I think just in the interest of time, we could always go much longer and deeper with everything going on in the oncology business. But thank you for the time. I think we'll have to leave it there, and we'll continue to follow the progress.